Citations

Clear

127 citation(s) found for "McCormick, A".

Comparison of Caspase Activation and Subcellular Localization in HL-60 and K562 Cells Undergoing Etoposide-Induced Apoptosis
Mesner, Peter W., Kottke, Timothy, Basi, Guriqbal S., Sinha, Sukanto, Tung, Jay S., Svingen, Phyllis A., Martins, L. Miguel , Madden, Benjamin J. , Takahashi, Atsushi, McCormick, Daniel , Earnshaw, William C. , Kaufmann, Scott H.

Mayo Clinic

Blood | October 13, 2019 | Volume: 90 | Issue: 11 | Pages: 4283-4296

10.1182/blood.v90.11.4283.4283_4283_4296 Get It

Previous studies have shown that K562 chronic myelogenous leukemia cells are resistant to induction of apoptosis by a variety of agents, including the topoisomerase II (topo II) poison etoposide, when examined 4 to 24 hours after treatment with an initiating stimulus. In the present study, the responses of K562 cells and apoptosis-proficient HL-60 acute myelomonocytic leukemia cells to etoposide were compared, with particular emphasis on determining the long-term fate of the cells. When cells were treated with varying concentrations of etoposide for 1 hour and subsequently plated in soft agar, the two cell lines displayed similar sensitivities, with a 90% reduction in colony formation at 5 to 10 μmol/L etoposide. After treatment with 17 μmol/L etoposide for 1 hour, cleavage of the caspase substrate poly(ADP-ribose) polymerase (PARP), DNA fragmentation, and apoptotic morphological changes were evident in HL-60 cells in less than 6 hours. After the same treatment, K562 cells arrested in G2 phase of the cell cycle but otherwise appeared normal for 3 to 4 days before developing similar apoptotic changes. When the etoposide dose was increased to 68 μmol/L, apoptotic changes were evident in HL-60 cells after 2 to 3 hours, whereas the same changes were observed in K562 cells after 24 to 48 hours. This delay in the development of apoptotic changes in K562 cells was accompanied by delayed release of cytochrome c to the cytosol and delayed appearance of peptidase activity that cleaved the fluorogenic substrates Asp-Glu-Val-Asp-aminotrifluoromethylcoumarin (DEVD-AFC) and Val-Glu-Ile-Asp-aminomethylcoumarin (VEID-AMC) as well as an altered spectrum of active caspases that were affinity labeled with N-(Nα-benzyloxycarbonylglutamyl-Nε-biotinyllysyl) aspartic acid [(2,6-dimethylbenzoyl)oxy]methyl ketone [z-EK(bio)D-aomk]. On the other hand, the activation of caspase-3 under cell-free conditions occurred with indistinguishable kinetics in cytosol prepared from the two cell lines. Collectively, these results suggest that a delay in the signaling cascade upstream of cytochrome c release and caspase activation leads to a long latent period before the active phase of apoptosis is initiated in etoposide-treated K562 cells. Once the active phase of apoptosis is initiated, the spectrum and subcellular distribution of active caspase species differ between HL-60 and K562 cells, but a similar proportion of cells are ultimately killed in both cell lines.
Identification of the Molecular Genetic Defect of Patients With Methemoglobin M Kankakee (M-Iwate), 87 (F8) His → Tyr: Evidence for an Electrostatic Model of M Hemoglobin Assembly
Ameri, Afshin, Fairbanks, Virgil F., Yanik, Greg, Mahdi, F., Thibodeau, Stephen N. , Boxer, Laurence A., McDonagh, Kevin T., McCormick, Daniel

Mayo Clinic

Blood | October 11, 2019 | Volume: 94 | Issue: 5 | Pages: 1825-1826

10.1182/blood.v94.5.1825.417k24_1825_1826 Get It

We determined that the molecular defect of 2 patients with hemoglobin (Hb) M-Kankakee [Hb M-Iwate, 87 (F8) His → Tyr] resides in the 1-globin gene. The proportion of Hb M observed is higher than that predicted for an 1-globin variant. Our evidence suggests that the greater-than-expected proportion of Hb M-Kankakee results from preferential association of the electronegative β-globin chains with the M-globin chains that are more electropositive than normal -globin chains.
Low-Pressure Lumbar Provocation Discography According to Spine Intervention Society/International Association for the Study of Pain Standards Does Not Cause Acceleration of Disc Degeneration in Patients With Symptomatic Low Back Pain
McCormick, Zachary L. , Plastaras, Christopher T. , Walega, David R., Huddleston, P.M. , Moussallem, Charbel D. , Geske, Jennifer R. , Verdoorn, Jared T. , Maus, Timothy P. , Lehman, Vance T. , Huddleston, Paul, Moussallem, Charbel, Carr, Carrie M. , Kennedy, David J. , Geske, Jennifer , Huddleston, Paul M

Mayo Clinic

Spine | July 1, 2019 | Volume: 44 | Issue: 19 | Pages: E1161-E1168

10.1097/brs.0000000000003085 | PMID 31261283 Get It

Study Design. Retrospective matched cohort study. Objective. To determine if low-pressure lumbar provocation discography (PD) results in long-term accelerated disc degeneration, internal disc disruption, or disc herniation in patients with symptomatic low back pain (LBP). Summary of Background Data. Study of subjects without clinically-significant LBP suggests that high-pressure PD may accelerate disc degeneration. Methods. Consecutive patients with symptomatic LBP who underwent magnetic resonance imaging (MRI), PD, and repeat MRI more than 7 years later, but did not undergo subsequent spinal fusion surgery, were included. Punctured discs were matched (1:2 to 1:4) to corresponding discs in a control cohort by age, BMI, Pfirrmann score (±2), and presence of disc herniation; control cohort inclusion required MRIs for symptomatic LBP, separated by more than 7 years. The primary outcome of the study was a progression in Pfirrmann score category (I–II, III–IV, V). MRI disc-to-CSF T2 signal-intensity ratio, disc height, disc herniations, high intensity zones (HIZs), and Modic changes were assessed. Results. Baseline and follow-up MRIs were available for 77 discs exposed to PD, and for 260 discs in the matched control cohort. There was no difference in the proportion of punctured discs that advanced in Pfirrmann score category in the PD group (17%, 95% CI 9–27%) compared with corresponding discs in the Control group (21%, 95% CI 17–27%), P = 0.3578, or in non-punctured discs in the PD group (35%, 95% CI 21–51%) compared with corresponding discs in the Control group (34%, 95% CI 27–42%), P = 0.1169. There were no differences in disc-to-CSF T2 signal-intensity ratio, presence of disc herniations, HIZs, or Modic changes following puncture in the PD versus matched cohort discs or in the non-punctured PD cohort discs versus corresponding control cohort discs (P > 0.05). Conclusion. Patients with symptomatic LBP who underwent low-pressure PD, but who did not undergo a subsequent spinal fusion surgery, developed disc degeneration and new disc herniations at a similar rate to corresponding discs in matched control patients. Level of Evidence: 3
Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.
Ganz, Patricia A. , White, Julia , Vicini, Frank A. , Julian, Thomas B. , Arthur, Douglas W., Rabinovitch, Rachel , Kuske, Robert R. , Parda, David S., Scheier, Michael F. , Winter, Kathryn, Kuerer, Henry M. , Vallow, Laura A., Pierce, Lori J. , Mamounas, Eleftherios P. , Costantino, Joseph P., Curran, Walter J. , Cecchini, Reena S. , Paik, Soonmyung , Mamounas, Eleftherios P. , McCormick, Beryl L. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 508-508

10.1200/jco.2019.37.15_suppl.508 Get It

508 Background: PBI is an alternative to WBI, with potentially greater therapy (tx) compliance, and better integration with chemotherapy (CTX). NSABP B-39/RTOG 0413 clinical outcome results from 2018 did not show equivalence of PBI to WBI in local tumor control; PBI was statistically inferior, but with clinically small differences. PBI may be an acceptable alternative to WBI for some women. Understanding cosmesis and quality of life (QOL) treatment outcomes is important. Methods: B-39/0413 included a prospective QOL substudy with PRO evaluation of breast cancer treatment outcomes (cosmesis, function, pain) and fatigue using BCTOS and SF-36 vitality scales. Secondary QOL parameters included treatment related symptoms, perceived convenience of care, and the BPI pain scale. The study sample was stratified by CTX or not, as CTX is given before WBI but after PBI. PRO assessments occurred before randomization, the last day of adjuvant tx [CTX or radiation], 4 wks later, and 6, 12, 24, and 36 mo later. Primary aims included comparisons of change in fatigue from baseline to end of tx and equivalency of change in cosmesis from baseline to 36 mo for PBI v WBI. Separate analyses were done for CTX and non-CTX pts, controlling for axillary dissection. Each comparison used α=0.0125. Planned sample size was 964. Results: From 3-23-05 to 5-27-09, 975 pts were enrolled in the PRO study; 950 had follow-up data. 504 did not receive CTX and 446 received CTX. In non-CTX pts, PBI had less fatigue (p=0.011) and did not meet criteria for cosmesis equivalence (97.5% CI, -0.02 to 0.22; ∆=0.20). In CTX pts, PBI had worse fatigue (p=0.011) and equivalent cosmesis to WBI (97.5% CI, -0.09 to 0.21; ∆=0.24). In both groups, PBI pts reported less pain at end of tx. In non-CTX pts, PBI had more pain at 36 mo but in CTX pts, there was no difference. Convenience of care and treatment related symptom outcomes will be presented. Conclusions: In non-CTX pts, PBI is more convenient with less fatigue and slightly poorer cosmesis at 36 mo. Cosmesis was equivalent at 36 mo in CTX pts. Support: U10CA180868, -180822, UG1CA189867. Clinical trial information: NCT00103181.
Managing the Unimaginable: Biobank Participant Views on Reconsent for Whole Genome Sequencing of Stored Biospecimens
Sutton, Erica J., Pacyna, Joel E. , Hathcock, Matthew , Nowakowski, K, Sharp, Richard R. , Sharp, Richard R , McCormick, Jennifer Blair , Olson, Janet E.

Mayo Clinic

Biopreservation and Biobanking | March 26, 2019 | Volume: 17 | Issue: 4 | Pages: 296-302

10.1089/bio.2018.0077 | PMID 30912675 Get It

Background: DNA biobanks frequently obtain broad permissions from sample donors, who agree to allow their biospecimens to be used for a variety of future purposes. A limitation of this approach is that it may not be possible to discuss or anticipate all potential uses of biospecimens at the time patient consent is obtained. We surveyed biobank participants to clarify their views regarding the need to be informed about research involving whole genome sequencing (WGS). Methods: We invited 1200 participants in the Mayo Clinic Biobank to complete a survey inquiring about their support for WGS; their interest in being recontacted before WGS of their biospecimens; whether they would consent to WGS if asked; and the acceptability of proceeding with WGS if sample donors could not be reached. Results: Six hundred eighty-seven biobank participants returned completed surveys (57% response). More than 96% of biobank participants were supportive of WGS and would give permission for WGS of their sample, if asked. Nonetheless, 61% of biobank participants felt they should be recontacted before WGS was done. Participants were divided regarding the permissibility of conducting WGS if efforts to recontact sample donors were unsuccessful. Discussion: Our findings highlight a potential discrepancy between the broad permissions granted by biobank participants at the time they donated biospecimens and their views about the application of WGS to their samples. Biobank participants appear to value the ability to confirm their commitment to genetic research when the studies in question involve WGS, a technological capacity they may not have anticipated at the time they donated their biospecimens. Efforts to reevaluate biobank participants' views about the acceptability of new technologies may help to ensure alignment of participants' current beliefs and research applications that would have been difficult to anticipate at the time biospecimens were collected.
Current Practice Trends in Image Guidance During Lumbar and Cervical Transforaminal Epidural Steroid Injections
Vydra, Darrell , Hynes, Alexander, Clements, Nate, Julia, Jonathon, Schneider, Byron J. , Maus, Timothy P. , Cushman, Daniel M. , McCormick, Zachary L. , Nagpal, Ameet

Mayo Clinic

Pain Medicine | March 12, 2019 | Volume: 20 | Issue: 11 | Pages: 2327-2329

10.1093/pm/pnz065 | PMID 30938803 Get It

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide
Meems, Laura M.G., Andersen, Ingrid A., Pan, Shuchong, Harty, Gail J., Zheng, Ye , Harders, Gerald E., Ichiki, Tomoko , Heublein, Denise M., Sangaralingham, S. Jeson , Burnett, John C. , Harty, Gail, Ichiki, Tomoki, Iyer, Seethalakshmi R., McCormick, Daniel J., Chen, Yang , Iyer, Seethalakshmi , Sangaralingham, S. Jeson , McCormick, Daniel

Mayo Clinic

Hypertension | February 25, 2019 | Volume: 73 | Issue: 4 | Pages: 900-909

10.1161/hypertensionaha.118.12012 | PMID 30798663 Get It

Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1–7 (angiotensin 1–7)—the 7-amino acid endogenous activator of MasR. We assessed NPA7’s dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7’s actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.
Enrichment sampling for a multi-site patient survey using electronic health records and census data
Mercaldo, Nathaniel D. , Brothers, Kyle B. , Connolly, John J. , Horowitz, Carol R. , Jarvik, Gail P. , Kitchner, Terrie, Li, Rongling, McCarty, Catherine A. , McManus, Valerie, Myers, Melanie F. , Pankratz, Joshua J., Shrubsole, Martha J. , Smith, Maureen E. , Stallings, Sarah , Williams, Janet L. , Schildcrout, Jonathan S. , McCormick, Jennifer B, Mercaldo, Nathaniel D , Myers, Melanie F , Shrubsole, Martha J , Schildcrout, Jonathan S , Jarvik, Gail P , Connolly, John J , Carrell, David , Clayton, Ellen Wright , Holm, Ingrid A. , McCormick, Jennifer Blair

Mayo Clinic

Journal of the American Medical Informatics Association | November 16, 2018 | Volume: 26 | Issue: 3 | Pages: 219-227

10.1093/jamia/ocy164 | PMID 30590688 Get It

Abstract Objective We describe a stratified sampling design that combines electronic health records (EHRs) and United States Census (USC) data to construct the sampling frame and an algorithm to enrich the sample with individuals belonging to rarer strata. Materials and Methods This design was developed for a multi-site survey that sought to examine patient concerns about and barriers to participating in research studies, especially among under-studied populations (eg, minorities, low educational attainment). We defined sampling strata by cross-tabulating several socio-demographic variables obtained from EHR and augmented with census-block-level USC data. We oversampled rarer and historically underrepresented subpopulations. Results The sampling strategy, which included USC-supplemented EHR data, led to a far more diverse sample than would have been expected under random sampling (eg, 3-, 8-, 7-, and 12-fold increase in African Americans, Asians, Hispanics and those with less than a high school degree, respectively). We observed that our EHR data tended to misclassify minority races more often than majority races, and that non-majority races, Latino ethnicity, younger adult age, lower education, and urban/suburban living were each associated with lower response rates to the mailed surveys. Discussion We observed substantial enrichment from rarer subpopulations. The magnitude of the enrichment depends on the accuracy of the variables that define the sampling strata and the overall response rate. Conclusion EHR and USC data may be used to define sampling strata that in turn may be used to enrich the final study sample. This design may be of particular interest for studies of rarer and understudied populations.
Regenerative Medicine: Ushering in a New Era in Pain Medicine
McCormick, Zachary L. , Hooten, Michael

Mayo Clinic

Pain Medicine | October 24, 2018 | Volume: 20 | Issue: 8 | Pages: 1459-1460

10.1093/pm/pny259 | PMID 30500942 Get It

The laser time out; Ensuring safe operation of lasers in the operating room suite
Ryan, Marthalane M., McCormick, Shari, Schaitberger, Sharli, Baldea, Barb, Hinni, Michael L.

Mayo Clinic

ILSC 2013: Proceedings of the International Laser Safety Conference | October 16, 2018 | Volume: No volume available | Issue: No issue available | Pages: 213-216

10.2351/1.5056793 Get It

Airway fires in the surgical suite are catastrophic and deadly. When there is a combination of an endotracheal (ET) tube filled with oxygen and an ignition source such as a laser, the standard ET tube acts like a blowtorch in the patient’s trachea. These tubes can be ignited at oxygen levels as low as 26% [1]. Laser safety programs should incorporate measures to isolate the triad that is present in all Operating Room (OR) fires: a source of oxygen, fuel, and ignition. Although safety hazards are inherent when lasers are used in the OR, they can be significantly reduced, if not eliminated, if proper procedures are implemented and adhered to whenever a laser is utilized in the OR. This article reviews the safety hazards and the implementation of a “Laser Time Out” to allow for the safe use of lasers in the Operating Room.